Prostate tumours from an Asian population: Examination of bax, bcl-2, p53 and ras and identification of bax as a prognostic marker

British Journal of Cancer

Volumn 83, Issue 6, 2000, Pages 761-768

  Chia, S J ^a   Tang, W Y ^a   Elnatan, J ^a   Yap, W M ^a   Goh, H S ^a   Smith, D R ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

Bax; Bcl 2; Immunohistochemistry; Mutation; p53; Survival

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; RAS PROTEIN; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; ASIA; CANCER SURVIVAL; ETHNIC DIFFERENCE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE TUMOR;

EID: 0033821939     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1355     Document Type: Article

References (44)

1. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas
2. p53 Nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy
3. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer
4. The apoptotic and transcriptional transactivation activities of p53 can be dissociated
5. Gene therapy for prostate cancer
6. The yin and yang of p53 in cellular proliferation
7. Association of p53 mutations with metastalic prostate cancer
8. Alterations of the P53 gene are associated with the progression of a human prostate carcinoma
9. C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas
10. A comparison of the detection of activated c-Ki-ras genes by mismatch specific oligonucleotide hybridisation analysis and enriched PCR in colorectal adenocarcinomas
11. Expression of bcl-2 and the progression of human and rodent prostatic cancers
12. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
13. Histological grading and clinical staging of prostate carcinoma
14. Future health issues and delivery needs of the elderly
15. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
16. Role of a mutant p53 protein in apoptosis: Characterization of a function independent of transcriptional trans-activation
17. Activated ras alleles in human carcinoma of the prostate are rare
18. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures
19. p53 And bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy
20. Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithclial neoplasia and localized prostate cancer: Relationship with apoptosis and proliferation
21. Comparison of ras activation in prostate carcinoma in Japanese and American men
22. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers
23. The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy
24. Prognostic significance of Ki-67, p53, and Bcl-2 expression in prostate cancer patients with lymph node metastases: A retrospective immunohistochemical analysis
25. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
26. Identification of a p53-dependent negative response element in the bcl-2 gene
27. Abnormalities of epithelial apoptosis in multistep colorectal neoplasia demonstrated by terminal deoxyoridine nick end labeling
28. Infrequent RAS oncogene mutations in human prostate cancer
29. Prognostic significance of Bcl-2, Bcl-xL/s, Bax and Bak expressions in colorectal carcinomas
30. The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different 'larget genes': A study of the TGFbeta RII, IGFII R, and BAX genes
31. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms
32. Mutations of ras genes are relatively frequent in Japanese prostate cancers: Pointing to genetic differences between populations
33. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer
34. A rapid and nonisotopic method for the screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumors
35. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas
36. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases
37. p53, bcl-2 And retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate
38. Microsatellite instability in cancer of the proximal colon
39. p53 Expression and clinical outcome in prostate cancer
40. Infrequent involvement of p53 gene mutations in the tumorigenesis of Japanese prostate cancer
41. p53 Gene mutations in human prostate cancers in Japan: Different mutation spectra between Japan and western countries
42. Movement of Bax from the cytosol to mitochondria during apoptosis
43. Proapoptotic gene BAX is frequently mutated in hereditary nonpolyposis colorectal cancers but not in adenomas